Program
tremelimumab
Also written as “Tremelimumab”, “CP-675,206” and “MEDI4736 + tremelimumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Melanoma · Small Cell Lung Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 4618 open or running | phase 3since Nov 18, 2005 | Jul 1, 2004 | Nov 30, 2026phase 2 · NCT07081633 |
| Pfizer | 10 open or running | phase 2since Jun 19, 2007 | Jun 19, 2007 | none ahead |
Also a collaborator on its studies: pra-health-sciences and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Jul 1, 2004.
- Nov 8, 2016Phase 1 study in Advanced MalignancyAstraZeneca · NCT02978482 · 26 enrolled · China
- Jan 18, 2017Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT03043872 · 987 enrolled · United States, Argentina, Austria and more
- May 22, 2017Phase 3 study in Non Small Cell Lung Cancer NSCLCAstraZeneca · NCT03164616 · 1,186 enrolled · United States, Brazil, Bulgaria and more
- Sep 19, 2017Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT03298451 · 1,324 enrolled · United States, Brazil, Canada and more
- Mar 12, 2018Phase 1 study in Squamous Cell Carcinoma of Head and NeckAstraZeneca · NCT03509012 · 105 enrolled · United States, Japan, Korea, Republic of and more
- Sep 6, 20182 phase 3 studiesAstraZeneca · NCT03682068, NCT03703297
- Jan 24, 2019Phase 2 study in NeoplasmsAstraZeneca · NCT03837899 · 50 enrolled · United States, France, Germany and more
- Jun 17, 2021Phase 3 study in Urinary Bladder NeoplasmsAstraZeneca · NCT04960709 · 712 enrolled · United States, Argentina, Austria and more
- Mar 21, 2022Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT05301842 · 760 enrolled · United States, Belgium, Brazil and more
- Sep 14, 2022Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT05557838 · 214 enrolled · China
- May 22, 2023Phase 3 study in Liver NeoplasmsAstraZeneca · NCT05883644 · 111 enrolled · United States, France, Germany and more
- Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06008093 · 103 enrolled · United States
- Mar 26, 2025Phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT06921785 · 1,220 planned · United States, Australia, Brazil and more
- Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633 · 114 enrolled · China, Hong Kong
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT07081633
- Mar 15, 2030Primary completion: phase 3 study in Carcinoma, HepatocellularAstraZeneca · NCT06921785
TargetBeta
“A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4)”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07081633Carcinoma, Hepatocellular · China, Hong Kong | 2 | Active, not recruiting | AstraZeneca | Nov 30, 2026 | 114 |
| NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Recruiting | AstraZeneca | Mar 15, 2030 | 1,220 |
| NCT06008093Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 103 |
| NCT05883644Liver Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | AstraZeneca | Mar 30, 2026 | 111 |
| NCT05557838Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | AstraZeneca | Sep 30, 2026 | 214 |
| NCT05301842Carcinoma, Hepatocellular · United States, Belgium, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Feb 23, 2026 | 760 |
| NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | Mar 2, 2026 | 712 |
| NCT03837899Neoplasms · United States, France, Germany and more | 2 | Active, not recruiting | AstraZeneca | Feb 28, 2023 | 50 |
| NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jan 15, 2024 | 730 |
| NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Jun 1, 2026 | 1,246 |
| NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more | 1 | Completed | AstraZeneca | Dec 31, 2020 | 105 |
| NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more | 3 | Active, not recruiting | AstraZeneca | Aug 27, 2021 | 1,324 |
| NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Mar 12, 2021 | 1,186 |
| NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Active, not recruiting | AstraZeneca | Jan 27, 2020 | 987 |
| NCT02978482Advanced Malignancy · China | 1 | Completed | AstraZeneca | Jan 28, 2018 | 26 |
| NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more | 2 | Completed | AstraZeneca | Jun 22, 2020 | 72 |
| NCT02658214Small Cell Lung Carcinoma · Japan, Korea, Republic of | 1 | Completed | AstraZeneca | Nov 14, 2019 | 32 |
| NCT02551159Squamous Cell Carcinoma of Head and Neck · United States, Austria, Belgium and more | 3 | Completed | AstraZeneca | Jul 6, 2020 | 823 |
| NCT02558894Anophthalmia with pulmonary hypoplasia · United States, Canada, Germany and more | 2 | Completed | AstraZeneca | Jun 15, 2017 | 65 |
| NCT02549651Lymphoma, Large B-Cell, Diffuse · United States, France, Ireland and more | 1 | Completed | AstraZeneca | Feb 4, 2019 | 32 |
| NCT02542293Non Small Cell Lung Carcinoma NSCLC · United States, Argentina, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 21, 2020 | 953 |
| NCT02527434Triple Negative Breast Neoplasms · United States, Belgium, Korea, Republic of and more | 2 | Completed | AstraZeneca | Feb 17, 2018 | 64 |
| NCT02519348Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | AstraZeneca | Nov 6, 2020 | 433 |
| NCT02516241Urothelial Cancer · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Jan 27, 2020 | 1,126 |
| NCT02453282Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Oct 4, 2018 | 1,118 |
| NCT02369874Recurrence · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Sep 10, 2018 | 736 |
| NCT02352948Non - Small Cell Lung Cancer NSCLC · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Feb 9, 2018 | 597 |
| NCT02340975Gastric or Gastroesophageal Junction Adenocarcinoma · United States, Canada, Japan and more | 2 | Completed | AstraZeneca | Apr 29, 2019 | 114 |
| NCT02319044Recurrence · United States, Australia, Belgium and more | 2 | Completed | AstraZeneca | Sep 26, 2016 | 267 |
| NCT02262741Squamous Cell Carcinoma of Head and Neck · United States, Canada | 1 | Completed | AstraZeneca | Sep 21, 2017 | 71 |
| NCT02261220Advanced Solid Tumors · United States, Canada, France and more | 1 | Completed | AstraZeneca | Jan 27, 2020 | 380 |
| NCT02179671Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | AstraZeneca | Jun 11, 2016 | 32 |
| NCT02141347Part A and B: Advanced Solid Malignancies · Japan | 1 | Completed | AstraZeneca | Jan 27, 2017 | 65 |
| NCT02117219Myelodysplastic Syndromes · United States, France, Germany and more | 1 | Completed | AstraZeneca | Apr 30, 2019 | 67 |
| NCT02000947Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 1 | Completed | AstraZeneca | Sep 17, 2019 | 459 |
| NCT01938612Squamous Cell Carcinoma of Head and Neck · Japan, Korea, Republic of, Taiwan | 1 | Completed | AstraZeneca | Mar 1, 2018 | 269 |
| NCT01843374Mesothelioma, Malignant · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Jan 24, 2016 | 571 |
| NCT00585000Melanoma · United States | 1 | Terminated | AstraZeneca | Jan 2010 | 49 |
| NCT00488995Acquired Immunodeficiency Syndrome | 2 | Withdrawn | Pfizer | 0 | |
| NCT00431275Melanoma · United States | 1 | Completed | AstraZeneca | Feb 2008 | 85 |
| NCT00378482Colorectal Neoplasms · United States, United Kingdom | 2 | Completed | AstraZeneca | Oct 27, 2023 | 37 |
| NCT00372853Carcinoma, Renal Cell · United States | 1 | Completed | AstraZeneca | May 2010 | 28 |
| NCT00313794Colorectal Neoplasms · United States, Canada | 2 | Completed | AstraZeneca | Jun 2008 | 49 |
| NCT00312975Carcinoma, Non-Small-Cell Lung · United States, Canada, Czech Republic and more | 2 | Completed | AstraZeneca | Apr 2008 | 90 |
| NCT00257205Melanoma · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Aug 2010 | 655 |
| NCT00254579Melanoma · United States, Argentina, Australia and more | 2 | Completed | AstraZeneca | Dec 2009 | 251 |
| NCT00086489Melanoma · United States | 2 | Completed | AstraZeneca | May 2007 | 118 |
How it is read
Names in the registry
- “Tremelimumab”, 22 entries
- “CP-675,206”, 12 entries
- “tremelimumab”, 7 entries
- “MEDI4736 + tremelimumab”, 3 entries
- “MEDI4736 + Tremelimumab”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Carcinoma, Hepatocellular, 6 studies
- Melanoma, 5 studies
- Small Cell Lung Carcinoma, 4 studies
- Squamous Cell Carcinoma of Head and Neck, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.